SALT LAKE CITY--(BUSINESS WIRE)--April 21, 2020--USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal first quarter ended March 28, 2020.

Key Financial & Operating Highlights

Global manufacturing and distribution remain fully operational.
Continued consumer demand and a successful promotion combine to generate $266.6 million in net sales during the quarter.
Company is following guidelines from government and health officials, to keep employees safe, including a work-from-home strategy for most employees and additional safety precautions for manufacturing and distribution employees.
Associates pivot to continue holding meetings and selling virtually/on-line.
Updated 2020 outlook reflects impact of a stronger U.S. dollar and continued uncertainty surrounding COVID-19.

Q1 2020 Financial Performance

Consolidated Results
Net Sales	$266.6 million	-2.3% vs. prior-year quarter +0.1% constant currency vs. prior-year quarter -$6.6 million fx impact, or -2.4%
Diluted EPS	$1.23	+21.8% vs. prior-year quarter Diluted shares of 21.6 million, -9.9%
Active Customers	573,000	-2.2% vs. prior-year quarter
Cash & Cash Equivalents	$194.1 million

The following information was filed by Usana Health Sciences Inc (USNA) on Tuesday, April 21, 2020 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

Please wait while we load the requested 10-Q report or click the link below:

https://last10k.com/sec-filings/report/896264/000156276220000164/usna-20200328x10q.htm

View differences made from one quarter to another to evaluate Usana Health Sciences Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Usana Health Sciences Inc.

Continue

Assess how Usana Health Sciences Inc's management team is paid from their Annual Proxy

Usana Health Sciences Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:

Voting Procedures
Board Members
Executive Team
Salaries, Bonuses, Perks
Peers / Competitors

Continue

Rating
Learn More

Filter Sentiment:

All

Positive

Negative

Filter Category:

All

Revenue

Financial

Other

Filter Subcategory:

All

Product

Cash Flow

Earnings

Geography

Income

Expense

Other

Inside Usana Health Sciences Inc's 10-Q Quarterly Report:

Revenue - Product Highlight
16 Quarters Ended March 28, 2020 and March 30, 2019 Net Sales The following table summarizes the changes in our net sales by geographic region for the fiscal quarters ended as of the dates indicated: Asia Pacific: The decrease in constant currency net sales in Greater China was largely the result of a sales decline in Mainland China, where local currency net sales decreased 6.3% due to a 10.0% decrease in active Customers.

Revenue - Product Highlight
We periodically make changes to our Compensation Plan in an effort to ensure that it is among the most competitive plans in the industry, to encourage behavior that we believe leads to a successful business for our Associates, and to ensure that our plan provides us with leverage to grow sales and earnings.
Financial - Cash Flow Highlight
Cash Flows Provided by Operations We have historically generated positive cash flow due to our strong operating margins.
Financial - Earnings Highlight
Gross Profit Gross profit decreased 50 basis points to 82.7% of net sales, down from 83.2% in the prior-year quarter.
Other - Other Highlight
Additionally, the initiatives we are executing under our customer experience, social media, and social sharing strategies are designed to promote active Customer growth.
Revenue - Geography
Americas and Europe: Constant currency...Read more
Financial - Income
Additionally, we believe that our...Read more
Revenue - Product
This decrease was due primarily...Read more
Revenue - Product
Measures taken to contain the...Read more
Revenue - Product
We are doing what we...Read more
Financial - Expense
The decrease can be attributed...Read more
Financial - Earnings
Net earnings for the first...Read more
Other - Other
We believe this focus is...Read more
Financial - Expense
This decrease can be attributed...Read more
Financial - Expense
Selling, General and Administrative Expenses...Read more
Revenue - Product
Customers Because we sell our...Read more
Revenue - Product
Results of Operations Summary of...Read more
Financial - Shares
The decrease is primarily due...Read more
Revenue - Geography
Consequently, as of the date...Read more
Financial - Expense
We also provide low cost...Read more
Other - Other
While the overall impact that...Read more
Financial - Earnings
Diluted Earnings per Share Diluted...Read more
Revenue - Geography
If SAFE or other Chinese...Read more
Other - Other
This non-GAAP financial information may...Read more
Other - Other
The GAAP reconciliations of these...Read more
Other - Other
We believe that these non-GAAP...Read more

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Material Contracts, Statements, Certifications & more

Usana Health Sciences Inc provided additional information to their SEC Filing as exhibits

Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 32.1: Section 1350 Certification

Exhibit 32.2: Section 1350 Certification

Ticker: USNA
CIK: 896264
Form Type: 10-Q Quarterly Report
Accession Number: 0001562762-20-000164
Submitted to the SEC: Tue May 05 2020 2:22:51 PM EST
Accepted by the SEC: Tue May 05 2020
Period: Saturday, March 28, 2020
Industry: Medicinal Chemicals And Botanical Products